Pharma Update
Broad hematology pipeline enabling novel combinations
A pioneer in bispecific antibodies and antibody drug conjugates
Phl
RG6076
englumafusp alfa
Heme tumors
RG6026
cevostamab
RG6160
r/r MM
RG6107
Ph II
Columvi
1L ctDNA high risk DLBCL
crovalimab
SCD
go go
RG7828
Ph III
RG6234
forimtamig
MM
RG6357
dirloctogene samoparvovec
Hemophilia A
IL 15/IL 15Ra-Fc
RG6323
Heme tumors
CD19 x CD28
RG6333
r/r NHL
Small molecule
ཏྠི ནྟི ཐཱཏི
2བ 1:|:ཀྱི
གླེང 1:|:ཀྱི ཀྱང 1 11:|:|:ཀྱི
སློང
RG6512
FIXax FX
Hemophilia
P-BCMA-ALLO1
RG6538*
MM
RG6026
Columvi
Heme tumors
Lunsumio
RG7828
Heme tumors
Antibody
Bispecifics
Gene therapy
Fusion protein
Antibody drug conjugate
Allogeneic CAR-T cells
RG6026
Columvi
2L+ DLBCL
RG6107
Registration
crovalimab
PNH
Lunsumio
2L+FL & 2L+ DLBCL
Launched
RG6107
crovalimab
aHUS
RG6026
Columvi
3L+ DLBCL
Venclexta
RG7601
RG7828
r/r MM & 1L MDS
Lunsumio
3L+ FL
RG7596
Polivy
1L & r/r DLBCL
RG7601
Venclexta
CLL & AML
RG6013
Hemlibra
Hemophilia A
Roche
RG7159
Gazyva
CLL & FL
MabThera
RG105
DLBCL, FL & CLL
*managed by Poseida Therapeutics; DLBCL-diffuse large B-cell lymphoma; FL-follicular lymphoma; CLL=chronic lymphocytic leukemia; MM-multiple myeloma; AML-acute myeloid leukemia; MDS=myelodysplastic
syndromes; PNH=Paroxysmal Nocturnal Hemoglobinuria; aHUS-atypical Hemolytic Uremic Syndrome; SCD=Sickle Cell Disease; NHL=Non-Hodgkins lymphoma; CAR-T-chimeric antigen receptor T-cell
84
==View entire presentation